Biologics and surgical outcomes in Crohn’s disease: is there a direct relationship?
Open Access
- 1 January 2020
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Gastroenterology
- Vol. 13
Abstract
Despite significant advances in medical therapy in the management of Crohn’s disease (CD), surgery is still required in a significant proportion of patients and constitutes an important tool in treatment algorithms. Recently, more options of biological agents have been made available, and most patients with CD undergoing surgical procedures have been previously exposed to this class of drugs. There is controversy in the literature as to whether anti-tumor necrosis factor (TNF) agents, anti-integrins, or anti-interleukins (ILs) have a direct relationship with increased postoperative complications. In this narrative review, the authors summarize the most important data regarding the effect of biologics on postoperative outcomes in CD. Most studies (with different designs) are based on the experience with anti-TNF agents, mostly with infliximab. Some studies outlined the relationship between vedolizumab and postoperative complications, and there is a lack of data with ustekinumab in this scenario. Most studies are retrospective, but few prospective data are available. A cause–effect (proof of concept) direct relationship between biologics and an increase in postoperative morbidity has not been demonstrated to date. Several confounding factors such as previous use of steroids, malnutrition, and unfavorable abdominal conditions have a definitely effect on postoperative complications in CD. Biologics seem safe to be used in the perioperative period, but available data are still controversial. Multidisciplinary individualized decisions should be made on a case-to-case basis, adapting the surgical strategy according to risk factors involved.Keywords
This publication has 55 references indexed in Scilit:
- Risk Factors for Surgical Site Infection and Association With Infliximab Administration During Surgery for Crohn’s DiseaseDiseases of the Colon & Rectum, 2013
- Vedolizumab as Induction and Maintenance Therapy for Crohn's DiseaseNew England Journal of Medicine, 2013
- Preoperative Infliximab Therapy Does Not Increase Morbidity and Mortality After Laparoscopic Resection for Inflammatory Bowel DiseaseDiseases of the Colon & Rectum, 2013
- Anti-tumor necrosis factor and postoperative complications in Crohnʼs disease: systematic review and meta-analysisInflammatory Bowel Diseases, 2012
- Pre‐operative use of anti‐TNF‐α agents and the risk of post‐operative complications in patients with Crohn's disease – a nationwide cohort studyAlimentary Pharmacology & Therapeutics, 2012
- Preoperative biological therapy and short-term outcomes of abdominal surgery in patients with inflammatory bowel diseaseGut, 2012
- Perioperative Anti-Tumor Necrosis Factor Therapy Does Not Increase the Rate of Early Postoperative Complications in Crohn’s DiseaseJournal of Gastrointestinal Surgery, 2010
- Use of Infliximab within 3 Months of Ileocolonic Resection is Associated with Adverse Postoperative Outcomes in Crohn’s PatientsJournal of Gastrointestinal Surgery, 2008
- Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn’s Disease: The CHARM TrialGastroenterology, 2007
- Maintenance infliximab for Crohn's disease: the ACCENT I randomised trialThe Lancet, 2002